Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Nosopharm
Nosopharm
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
French collaboration aims to address antibiotic resistance
The project will involve the creation of chemical libraries of bioactive molecules for Nosopharm’s anti-infective screening campaigns against antibiotic resistance
Recruitment
Nosopharm bolsters supervisory board
Research & Development
Nosopharm joins European Gram-negative Antibacterial Engine (ENABLE) project to combat antibiotic resistance
The company aims to advance a promising antibacterial compound to clinical stage for the treatment of multidrug-resistant Gram-negative infections
Research & Development
Nosopharm secures funding of €870,000 to fight antibiotic resistance
Nosopharm has developed a new class of antibiotics and the funding will ensure their progression to preclinical development
Subscribe now